Cytokines & engineered cytokines
Cytokine therapy gives immune-signalling proteins as drugs. High-dose interleukin-2 was the first immunotherapy to cure some melanomas, at great toxicity.
High-dose IL-2 and interferon-alpha are historic. Engineered IL-2 (bempegaldesleukin failed), IL-15 superagonists (nogapendekin alfa/Anktiva, approved 2024 with BCG in bladder cancer), IL-12 (tavokinogene, intratumoural), and tumour-targeted immunocytokines are the modern forms. IL-2 remains part of TIL therapy regimens.
How it works
Systemic or targeted delivery of T- and NK-cell growth factors.
- Potent immune expansion
- Systemic toxicity; preferential Treg expansion (IL-2)
High-dose interleukin-2 was the first immunotherapy to cure a small fraction of patients with metastatic melanoma and kidney cancer, at the cost of ICU-level toxicity; today it mainly supports TIL therapy.
Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials.
Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents.
An immune-activating drug approved in Europe for osteosarcoma after a trial suggested it improved survival; the FDA never approved it, and it remains one of oncology's transatlantic disagreements.
Nogapendekin alfa inbakicept is an engineered version of the immune-boosting protein IL-15, given with BCG into the bladder, approved in 2024 for early bladder cancer that BCG alone no longer controls.
Ropeginterferon alfa-2b is a long-acting interferon for polycythaemia vera that, unlike hydroxyurea, can shrink the mutant clone over years.
Latest papers
topQuery for this technology: (TITLE:"engineered cytokine" OR ABSTRACT:"engineered cytokine" OR TITLE:"IL-2 variant" OR ABSTRACT:"IL-2 variant" OR TITLE:"IL-15 superagonist" OR ABSTRACT:"IL-15 superagonist") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cytokines & engineered cytokines, not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologySTING & innate immune agonists
Shares Engineered bacteria as living cancer drugs, Inhaled immune therapy to make the lung hostile to arriving tumour cells, Engineered bacteria that live in tumours and manufacture drugs there, In situ vaccination.
- TechnologyOncolytic viruses
Shares Engineered bacteria as living cancer drugs, Intratumoural gene electrotransfer (IL-12 plasmid), In situ vaccination, Oncolytic viruses that make interleukin-12 only inside the tumour.
- TechnologyIntravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)
Shares Trained innate immunity, Nogapendekin alfa inbakicept, Engineered bacteria that live in tumours and manufacture drugs there, Bladder & urothelial cancer.
- TermBCG-unresponsive
Shares QUILT 3.032, Nogapendekin alfa inbakicept, NK-cell recognition: missing self & stress ligands, Bladder & urothelial cancer.
- ProductIntravesical BCG
Shares QUILT 3.032, Engineered bacteria that live in tumours and manufacture drugs there, Bladder & urothelial cancer.
- ProductVusolimogene oderparepvec
Shares Oncolytic viruses that make interleukin-12 only inside the tumour, Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity, Cold tumours and the immunosuppressive microenvironment, Melanoma.
- TechnologyTIL therapy
Shares Aldesleukin (high-dose IL-2), Steven A. Rosenberg, NCI Center for Cancer Research (intramural programme), T-cell exhaustion.
- TargetCD47
Shares Inhaled immune therapy to make the lung hostile to arriving tumour cells, Engineered bacteria that live in tumours and manufacture drugs there, Cold tumours and the immunosuppressive microenvironment.